Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.2.u1
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three months ended June 30, 

​

Six Months Ended June 30, 

​

    

2024

    

2023

    

2024

    

2023

Revenue

​

​

​

​

​

​

​

​

​

​

​

​

Qbrexza

​

$

6,836

​

$

8,079

​

$

11,853

​

$

12,173

Accutane

​

​

5,719

​

​

5,579

​

​

11,538

​

​

10,227

Amzeeq

​

​

1,205

​

​

1,374

​

​

1,960

​

​

2,568

Zilxi

​

​

369

​

​

572

​

​

642

​

​

886

Other / legacy product revenue

​

​

726

​

​

1,357

​

​

1,892

​

​

3,272

Collaboration revenue

​

​

—

​

​

183

​

​

—

​

​

364

Revenue – related party

​

 

41

​

 

31

​

 

41

​

 

66

Other revenue

​

​

—

​

​

211

​

​

—

​

 

259

Total net revenue

​

$

14,896

​

$

17,386

​

$

27,926

​

$

29,815